Cargando…

A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy

BACKGROUND: Delineation of clinical target volume (CTV) for radiotherapy is a time‐consuming and labor‐intensive work. This study aims to propose a novel convolutional neural network (CNN)‐based model for fast auto‐segmentation of CTV. To evaluate its performance and clinical utility, a blind random...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yijun, Kang, Kai, Han, Chang, Wang, Shaobin, Chen, Qi, Chen, Yu, Zhang, Fuquan, Liu, Zhikai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704175/
https://www.ncbi.nlm.nih.gov/pubmed/34811957
http://dx.doi.org/10.1002/cam4.4441
_version_ 1784621643637719040
author Wu, Yijun
Kang, Kai
Han, Chang
Wang, Shaobin
Chen, Qi
Chen, Yu
Zhang, Fuquan
Liu, Zhikai
author_facet Wu, Yijun
Kang, Kai
Han, Chang
Wang, Shaobin
Chen, Qi
Chen, Yu
Zhang, Fuquan
Liu, Zhikai
author_sort Wu, Yijun
collection PubMed
description BACKGROUND: Delineation of clinical target volume (CTV) for radiotherapy is a time‐consuming and labor‐intensive work. This study aims to propose a novel convolutional neural network (CNN)‐based model for fast auto‐segmentation of CTV. To evaluate its performance and clinical utility, a blind randomized validation method was used. METHODS: Our proposed model was based on the generally accepted U‐Net architecture using computed tomography slices with CTV contours delineated by experienced radiation clinicians from 135 rectal patients receiving neoadjuvant radiotherapy. The Dice similarity coefficient (DSC) and 95th percentile Hausdorff distance (95HD) were used to measure segmentation performance. The validated dataset of additional 20 patients for clinical evaluation by 10 experienced oncology clinicians from 7 centers was randomly and blindly divided into two groups for clinicians' scoring and Turing test, respectively. Second evaluation was performed with different randomization after 2 weeks. RESULTS: The mean DSC and 95HD values of the proposed model were 0.90 ± 0.02 and 8.11 ± 1.93 mm for CTV of rectal cancer patients, respectively. The average time for automatic segmentation in the validation groups was 15 s per patient. By clinicians' scoring, the AI model performed better than manually delineating, though the differences were not significant (Week 0: 2.59 vs. 2.52, p = 0.086; Week 2: 2.55 vs. 2.47, p = 0.115). Additionally, the mean positive rates in the Turing test were 40.5% in Week 0 and 45.2% in Week 2, which demonstrated the great intelligence of our model. CONCLUSIONS: Our proposed model can be used clinically for assisting contouring of CTVs in rectal cancer patients receiving neoadjuvant radiotherapy, which improves the efficiency and consistency of radiation clinicians' work.
format Online
Article
Text
id pubmed-8704175
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-87041752022-01-04 A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy Wu, Yijun Kang, Kai Han, Chang Wang, Shaobin Chen, Qi Chen, Yu Zhang, Fuquan Liu, Zhikai Cancer Med Clinical Cancer Research BACKGROUND: Delineation of clinical target volume (CTV) for radiotherapy is a time‐consuming and labor‐intensive work. This study aims to propose a novel convolutional neural network (CNN)‐based model for fast auto‐segmentation of CTV. To evaluate its performance and clinical utility, a blind randomized validation method was used. METHODS: Our proposed model was based on the generally accepted U‐Net architecture using computed tomography slices with CTV contours delineated by experienced radiation clinicians from 135 rectal patients receiving neoadjuvant radiotherapy. The Dice similarity coefficient (DSC) and 95th percentile Hausdorff distance (95HD) were used to measure segmentation performance. The validated dataset of additional 20 patients for clinical evaluation by 10 experienced oncology clinicians from 7 centers was randomly and blindly divided into two groups for clinicians' scoring and Turing test, respectively. Second evaluation was performed with different randomization after 2 weeks. RESULTS: The mean DSC and 95HD values of the proposed model were 0.90 ± 0.02 and 8.11 ± 1.93 mm for CTV of rectal cancer patients, respectively. The average time for automatic segmentation in the validation groups was 15 s per patient. By clinicians' scoring, the AI model performed better than manually delineating, though the differences were not significant (Week 0: 2.59 vs. 2.52, p = 0.086; Week 2: 2.55 vs. 2.47, p = 0.115). Additionally, the mean positive rates in the Turing test were 40.5% in Week 0 and 45.2% in Week 2, which demonstrated the great intelligence of our model. CONCLUSIONS: Our proposed model can be used clinically for assisting contouring of CTVs in rectal cancer patients receiving neoadjuvant radiotherapy, which improves the efficiency and consistency of radiation clinicians' work. John Wiley and Sons Inc. 2021-11-23 /pmc/articles/PMC8704175/ /pubmed/34811957 http://dx.doi.org/10.1002/cam4.4441 Text en © 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Wu, Yijun
Kang, Kai
Han, Chang
Wang, Shaobin
Chen, Qi
Chen, Yu
Zhang, Fuquan
Liu, Zhikai
A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy
title A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy
title_full A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy
title_fullStr A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy
title_full_unstemmed A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy
title_short A blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy
title_sort blind randomized validated convolutional neural network for auto‐segmentation of clinical target volume in rectal cancer patients receiving neoadjuvant radiotherapy
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8704175/
https://www.ncbi.nlm.nih.gov/pubmed/34811957
http://dx.doi.org/10.1002/cam4.4441
work_keys_str_mv AT wuyijun ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT kangkai ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT hanchang ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT wangshaobin ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT chenqi ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT chenyu ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT zhangfuquan ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT liuzhikai ablindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT wuyijun blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT kangkai blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT hanchang blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT wangshaobin blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT chenqi blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT chenyu blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT zhangfuquan blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy
AT liuzhikai blindrandomizedvalidatedconvolutionalneuralnetworkforautosegmentationofclinicaltargetvolumeinrectalcancerpatientsreceivingneoadjuvantradiotherapy